JVM
Financials
Valuation Metrics
JVM's Market Cap is ₩2805B. At end of 2025 it was ₩3125B. Ranked #693 of 2,421 in KR market (top 29%), #293 of 1,640 on KOSDAQ (top 18%), #120 of 361 in Capital Goods (top 33%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 280.49B KRW | KR#693/2,421 Sec#120/361 |
| Revenue | 177.56B KRW | KR#1,096/2,421 Sec#189/361 |
| Net Income | 30.85B KRW | KR#552/2,421 Sec#104/361 |
| Total Assets | 336.65B KRW | KR#974/2,421 Sec#167/361 |
| Net Assets | 245.83B KRW | KR#833/2,421 Sec#146/361 |
| Employees | 317 | KR#759/2,421 Sec#137/361 |
| Value | ||
| P/E | 9.09x | KR#745/2,421 Sec#109/361 |
| P/B | 1.14x | KR#1,574/2,421 Sec#215/361 |
| P/S | 1.58x | KR#1,667/2,421 Sec#238/361 |
| EV/EBITDA | 8.26x | KR#499/2,421 Sec#64/361 |
| FCF Yield | 10.16% | KR#599/2,421 Sec#92/361 |
| Profitability | ||
| ROE | 12.55% | KR#439/2,421 Sec#76/361 |
| ROA | 9.16% | KR#332/2,421 Sec#50/361 |
| Op. Margin | 20.46% | KR#156/2,421 Sec#21/361 |
| Revenue Growth | 3.30% | KR#1,305/2,421 Sec#184/361 |
| Earnings Growth | -1.19% | KR#836/2,421 Sec#130/361 |
| Financial Health | ||
| Debt Ratio | 36.94% | KR#729/2,421 Sec#86/361 |
| Total Debt | 34.87B KRW | KR#1,155/2,421 Sec#204/361 |
| FCF | 28.49B KRW | KR#429/2,421 Sec#83/361 |
| Cash | 15.44B KRW | KR#1,409/2,421 Sec#232/361 |
| Current Ratio | 2.72x | KR#628/2,421 Sec#63/361 |
| Net Debt/EBITDA | 0.54x | KR#681/2,421 Sec#85/361 |
| Dividend | ||
| Div. Yield | 2.82% | KR#677/2,421 Sec#89/361 |
| Div. Growth | 30.00% | KR#365/2,421 Sec#74/361 |
| Performance | ||
| 1Y Return | -29.38% | KR#1,546/2,421 Sec#256/361 |
| 1M Return | -2.73% | KR#1,558/2,421 Sec#256/361 |
| From 52W High | -32.26% | KR#613/2,421 Sec#80/361 |
| 1Y MDD | -39.94% | KR#582/2,421 Sec#67/361 |
| Trading | ||
| Volume | 10,071 shares | KR#1,913/2,421 Sec#314/361 |
| Trading Value | 234.9M KRW | KR#1,213/2,421 Sec#229/361 |
| Foreign Own. | 19.85% | KR#230/2,421 Sec#42/361 |
| Per Share | ||
| EPS | 2,551 KRW | KR#388/2,421 Sec#68/361 |
| BPS | 20,334 KRW | KR#538/2,421 Sec#94/361 |
Company Info
JVM, established in 1977 for equipment development, production, and sales, was listed on KOSDAQ in 2006 and became a subsidiary of Hanmi Pharmaceutical Group in 2016. The company researches, develops, produces, and sells hospital and pharmacy automation systems and related software using its proprietary technology, boasting a diverse product lineup. JVM focuses on R&D and production of next-generation products, supplying equipment to 60 countries through global partners to expand its market presence. It is headquartered in Dalseo-gu, Daegu Metropolitan City.